Early Use of Surfactant-BL after Lung Transplantation

Goal. To evaluate the clinical effect of early administration of surfactant-BL on pulmonary oxygenizing function and biomechanics in patients early after lung transplantation (LT). Materials and methods. Seven patients early after transplantation were administered with a surfactant-BL («Biosurf», St.-Petersburg, RF) to prevent or treat primary lung transplant disfunction. Results and conclusions. Multiple endobronchial administration of surfactant-BL (0, 24, and 48 hours) resulted in a progressive increase in the ratio of arterial oxygen partial pressure by an average of 94 mm Hg (p<0.05) to oxygen fraction in a respiratory mixture ( РаО2^Ю2) at 48 hours after the surgery and by an average 1.2-fold increase in dynamic thoracopulmonary compliance accompanied by a reduction in the magnitude of PLGD. Employed protocol of surfactant-BL administration was favorable for optimizing the biomechanical properties and oxygenizing function of the lung. The findings clearly demonstrate that the early administration of surfactant-BL after LT should benefit the comprehensive prevention and treatment of PLGD that complicates the early postoperative period after LT.

lung transplantation, primary lung graft dysfunction, pulmonary surfactant system, surfactant-BL, mechanical ventilation, pulmonary oxygenizing dysfunction, extracorporeal membrane oxygenation.

1. . Thabut G., Vinatier I., SternJ.B., Lemche G., Loirat P., FournierM., MaiH.Chest.

2. Christie J.D., Van Raemdonck D., de Perrot M., Barr M., Keshavjee S., Arcasoy S.M., Orens J.; ISHLT Working Group on Primary Lung Graft Dysfunction.Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods.J. Heart Lung Transplant.2005; 24 (10): 1451—1453.

3. Arcasoy S.M., Fisher A., Hachem R.R., Scavuzzo M., Ware L.B.; ISHLT Working Group on Primary Lung Graft Dysfunction.Report of the ISHLT Working Group on Primary Lung Dysfunction part V: predictors and outcomes.J. Heart Lung Tansplant.2005; 24 (10): 1483—1488.

4. Lee J.C., Christie J.D., Keshavjee S.Primary graft dysfunction: definition, risk, factors, short-and long-term outcomes.Semin. Respir. Crit. Care Med.2010; 31 (2): 161 — 171.

5. Christie J.D., Kotloff R.M., Pochettino A., Arcasoy S.M., Rosengard B.R., Landis J.R.., Kimmel S.E.Clinical risk factors for primary graft failure following lung transplantation.Chest.2003; 124 (4): 1232—1241.

6. King R.C., Binns O.A., Rodriguez F., Kanithanon R.C., Daniel T.M., Spotnitz W.D., Tribble C.G., Kron I.L.Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.Ann. Thorac. Surg.2000; 69 (6): 1681—1685.

7. Knudsen L., Boxler L., Muhlfeld C., Schaefer I.M., Becker L., Bussinger C., von Stietencron I., Madershahian N., Richter J., Wahlers T., Wittwer T., Ochs M.Lung preservation in experimental ischemia/reperfusion injury and lung transplantation: a comparison of natural and synthetic surfactants.J. Heart Lung Transplant.2012; 31 (1): 85—93.

8. Spragg R.Abnormalities of lung surfactant function in patients with acute lung injury. In: Adult respiratory distress syndrome.Zapol W., Lemaire F. (eds.).New York: Marcel Dekker; 1991: 381—395.

9. Hallman M., Spragg R., Harrell J.H., Moser K.M., Gluck L.Evidence of lung surfactant abnormality in respiratory failure. Study of bron-choalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol.J. Glin. Invest.1982; 70 (3): 673—683.

10. Голубев А.М., Мороз В.В., Сундуков Д.В.Патогенез острого респираторного дистресс-синдрома.Общая реаниматология.2012; 8 (4): 13—21.

11. Марченков Ю.В., Власенко А.В., Мороз В.В., Яковлев В.Н.Эволюция диагностики и лечения острого респираторного дистресс-синдрома на основе новейших медицинских технологий.Общаяреаниматология.2012; 8 (4): 22—29.

12. Duggan M., Kavanagh B.P.Pulmonary atelectasis: a pathogenic periop-erative entity.Anesthesiology.2005; 102 (4): 838—854.

13. Власенко А.В., Мороз В.В., Яковлев В.Н., Алексеев В.Г., Булатов Н.Н.Выбор способа оптимизации ПДКВ у больных с острым респираторным дистресс-синдромом.Общая реаниматология.2012; 8 (1): 13—21.

14. Мороз В.В., Власенко А.В., Яковлев В.Н., Алексеев В.Г.Оптимизация ПДКВ у больных с острым респираторным дистресс-синдромом, вызванным прямыми и непрямыми повреждающими факторами.Общаяреаниматология.2012; 8 (3): 5—13.

15. Baker C.S., Evans T.W., Randle B.J., Haslam P.L.Damage to surfactant-specific protein in acute respiratory distress syndrome.Lancet.1999; 353 (9160): 1232—1237.

16. Lachmann B.Open up the lung and keep the lung open.Intensive Care Med.1992; 18 (6): 319—321.

17. КозловИ.А., РомановАА.Маневр открытия («мобилизация») альвеол при интраоперационном нарушении оксигенирующей функции легких у кардиохирургических больных.Анестезиологияиреаниматология.2007; 2: 27—30.

18. Christie J.D., Carby M., Bag R., Corris P., Hertz M., Weill D.; ISHLT Working Group on Primary Lung Graft Dysfunction.Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation.J. Heart Lung Transplant.2005; 24 (10): 1454—1459.

19. Verbrugge SJ., Bohm S.H., Gommers D., Zimmerman LJ., Lachmann B.Surfactant impairment after mechanical ventilation with large alveolar surface area changes and effects of positive end-expiratory pressure.Br. J. Anesth.1998; 80 (3): 360—364.

20. HohlfeldJ.M., Tiryaki E., Hamm H., Hoymann H.G., KrugN., Haverich A., Fabel H.Pulmonary surfactant activity is impaired in lung transplant recipients.Am. J. Respir. Crit. Care Med.1998; 158 (3): 706—712.

21. Ochs M., Nenadic I., Fehrenbach A., Albes J.M., Wahlers T., Richter J., Fehrenbach H.Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion.Am. J. Respir. Crit. Care Med.1999; 160 (2): 718—724.

22. Minambres E., Gonzalez-Castro A., Rabanal J.M., Suberviola B., Ortega FJ., Zurbano F, Dfaz-Reganon G., LlorcaJ.Comparative study of two preservation solutions in the initial function after bilateral human lung transplantation.Med. Intensiva.2007; 31 (1): 1—5.

23. Suarez Lopeza V.J., Minambresa E., Robles Arista J.C., Ballesteros MA.Primary graft dysfunction after lung transplantation.Med. Intensiva.2012; 36 (7): 506—512.

24. Struber M, HirtS.W.,Cremer J., Harringer W., Haverich A.I.Surfactant replacement injury after clinical lung transplantation.Intensive Care Med.1999; 25 (8): 862—864.

25. Friedrich I, Splittgerber F.H., Gunther A.Influence of transbronchial surfactant administration on lung function and surfactant attributes after single lung transplantation.J. Heart Lung Transplant.1997; 16 (1): 113.

26. Eisner M.D., Parsons P., Matthay MA., Greene K.Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury.Thorax.2003; 58 (11): 983—988.

27. ChengI.W., Ware L.B., Greene K.E., Nuckton TJ., Eisner M.D., Matthay MA.Prognostic value of surfactant proteins A and D in patients with acute lung injury.Crit. Care Med.2003; 31 (1): 20—

28. Shah R.J., Bellamy S.L., Localio A.R., Wickersham N., Diamond J.M., Weinacker A., Lama V.N., Bhorade S., BelperioJA., Crespo M., DemissieE., Kawut S.M., Wille K.M., Lederer DJ., Lee J.C., Palmer S.M., Orens J., Reynolds J, Shah A., Wilkes D.S., Ware L.B., ChristieJ.D.A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.J. Heart Lung Transplant.2012; 31 (9): 942—949.

29. Розенберг О.А.Легочный сурфактант и его применение при заболеваниях легких.Общаяреаниматология.2007; 3 (1): 66—77.

30. Veldhuizen R.A., Marcou J., Yao LJ., McCaig L., Ito Y., Lewis J.F.Alveolar surfactant aggregate conversion in ventilated normal and injured rabbits.Am. J. Physiol1996; 270 (1 Pt 1): L152—L158.

31. Van Iwaarden F.J., van Golde L.Pulmonary surfactant and lung defense. Surfactant therapy for lung disease. In: Lung biology in health and disease.Robertson B., Taeusch H.W. (eds.).N.Y.: Marcel Dekker Inc.; 1995: 75-84.

32. Козлов ИА., Выжигина МА., Мещеряков Г.А.Сурфактантная система легких.Анестезиологияиреаниматология.1984; 2: 68—73.

33. Erasmus M.E., Hofstede GJ., Petersen A.H., Batenburg JJ., Haagsman H.P., Oetomo S.B., Prop J.SP-A enriched surfactant for treatment of rat lung transplants with SP-A deficiency after storage and reperfusion.Transplantation.2002; 73 (3): 348—352.

34. Struber M., Fischer S., NiedermeyerJ., Warnecke G., Gohrbandt B., Gorier A., Simon A.R., Haverich A., Hohlfeld J.M.Effects of exogenous surfactant instillation in clinical lung transplantation; a prospective, randomized trial.J. Thorac. Cardiovasc. Surg.2007; 133 (6): 1620—1625.

35. AmitalA., ShitritD., Raviv Y., SauteM., Medalion B., BakalL., KramerM.R.The use of surfactant in lung transplantation.Transplantation.2008; 86 (11): 1554—1559.